ACTA1 and Hepatic fibrosis: The administration of GP/HH-F3 significantly inhibited the DEN-induced serum markers AST, ALT, and γ-GT; it also decreased α-SMA and collagen expression, alleviated liver fibrosis, and largely improved liver functional injury in rats.